Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report)'s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of C$9.08 and traded as high as C$10.14. Fennec Pharmaceuticals shares last traded at C$10.14, with a volume of 1,834 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Stephens upgraded Fennec Pharmaceuticals to a "strong-buy" rating in a research report on Monday, November 18th.
Read Our Latest Stock Analysis on FRX
Fennec Pharmaceuticals Stock Down 0.8 %
The company has a debt-to-equity ratio of -620.83, a quick ratio of 10.17 and a current ratio of 7.80. The firm has a market capitalization of C$186.87 million, a PE ratio of -164.15 and a beta of 0.25. The company has a fifty day moving average price of C$9.14 and a 200-day moving average price of C$7.84.
Insiders Place Their Bets
In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov sold 10,000 shares of the company's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of C$8.76, for a total transaction of C$87,552.00. Insiders sold 13,617 shares of company stock valued at $122,514 in the last three months. Corporate insiders own 16.20% of the company's stock.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Further Reading
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
